TY - JOUR
T1 - Advanced Breast Cancer Guidelines in Latin America
T2 - Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus Guidelines
AU - Valencia, Fernando
AU - Gómez, Henry L.
AU - Neciosup, Silvia P.
AU - Limón, Ronald
AU - Torrico, María Del Carmen
AU - Morillas, Lena
AU - Torres, Roberto
AU - Sánchez, Cesar
AU - Araya, Ingiborg
AU - Gómez, Rodolfo
AU - Bruges, Ricardo
AU - Vargas, Carlos
AU - Soria, Tannia
AU - Muñoz, René
AU - Riofrío, Mauricio
AU - Gálvez, Marco
AU - Ruiz, Rossana
AU - Benites, Pilar
AU - Cardoso, Fatima
N1 - Publisher Copyright:
© 2024 American Society of Clinical Oncology.
PY - 2024/2/1
Y1 - 2024/2/1
N2 - PURPOSEAs the fifth international consensus on advanced breast cancer (ABC5) established guidelines for the management of this disease, the aim of this article was to present the applicability of the consensus recommendations and to generate knowledge to improve access.METHODSSixty-one recommendation statements were selected and discussed by 15 breast cancer experts from Latin America (LA). After the discussion, the level of consensus was determined through a vote. In addition to this, the level of access to each of the recommendations presented, according to the country and health system, was exposed.RESULTSLatin American experts had a high level of agreement with the ABC5 consensus recommendations (range, 83%-100%). Twelve of 61 statements are not available for all patients in LA. Among the limitations to access, the following ones are described: limited access to certain technologies (stereotactic body radiotherapy, positron emission tomography-computed tomography), the high costs of drugs that limits access to treatment with CDK4/6 inhibitors, pertuzumab, or poly(ADP-ribose) polymerase inhibitors, and the lack of molecular tests for access to therapeutic targets, as well as the difficult geography and cultural diversity of our continent.CONCLUSIONDespite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region.
AB - PURPOSEAs the fifth international consensus on advanced breast cancer (ABC5) established guidelines for the management of this disease, the aim of this article was to present the applicability of the consensus recommendations and to generate knowledge to improve access.METHODSSixty-one recommendation statements were selected and discussed by 15 breast cancer experts from Latin America (LA). After the discussion, the level of consensus was determined through a vote. In addition to this, the level of access to each of the recommendations presented, according to the country and health system, was exposed.RESULTSLatin American experts had a high level of agreement with the ABC5 consensus recommendations (range, 83%-100%). Twelve of 61 statements are not available for all patients in LA. Among the limitations to access, the following ones are described: limited access to certain technologies (stereotactic body radiotherapy, positron emission tomography-computed tomography), the high costs of drugs that limits access to treatment with CDK4/6 inhibitors, pertuzumab, or poly(ADP-ribose) polymerase inhibitors, and the lack of molecular tests for access to therapeutic targets, as well as the difficult geography and cultural diversity of our continent.CONCLUSIONDespite the great relevance of the recommendations of the ABC5 consensus guidelines, we highlight that we still need to improve access for all patients, regardless of the country or health system they are in, for which we call to action to policy makers and patient groups to improve clinical outcomes of patients with advanced breast cancer in our region.
UR - http://www.scopus.com/inward/record.url?scp=85184345261&partnerID=8YFLogxK
U2 - 10.1200/GO.22.00067
DO - 10.1200/GO.22.00067
M3 - Article
C2 - 38301184
AN - SCOPUS:85184345261
SN - 2687-8941
VL - 10
JO - JCO global oncology
JF - JCO global oncology
M1 - e2200067
ER -